Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 106,543 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $225.46, for a total value of $24,021,184.78. Following the completion of the transaction, the director owned 1,172,289 shares in the company, valued at approximately $264,304,277.94. The trade was a 8.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Illumina Price Performance
ILMN stock opened at $227.69 on Friday. The business has a 50 day moving average price of $192.98 and a 200 day moving average price of $155.18. The stock has a market cap of $34.38 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 3.16 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $231.81. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the firm posted $1.19 earnings per share. The firm's revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Illumina
Institutional investors and hedge funds have recently made changes to their positions in the business. Elyxium Wealth LLC purchased a new position in shares of Illumina during the fourth quarter worth about $25,000. TD Waterhouse Canada Inc. purchased a new stake in Illumina during the 4th quarter valued at approximately $26,000. Laurel Wealth Advisors LLC purchased a new stake in Illumina during the 4th quarter valued at approximately $26,000. Fiduciary Financial Advisors acquired a new stake in Illumina during the 2nd quarter worth approximately $26,000. Finally, Activest Wealth Management lifted its position in Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after acquiring an additional 215 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
ILMN has been the topic of several research analyst reports. Stifel Nicolaus lifted their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Daiwa Securities Group upgraded shares of Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 price objective for the company in a research note on Thursday, May 14th. Piper Sandler restated an "overweight" rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Evercore reiterated an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Finally, Zacks Research raised Illumina from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of "Hold" and an average price target of $188.40.
View Our Latest Report on ILMN
Illumina Company Profile
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
